Longeveron (LGVN) Price & Analysis

Compare

557 Followers

LGVN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.14 - $2.89

Previous CloseN/A

Volume215.49K

Average Volume (3M)605.78K

Market Cap

$23.26M

Enterprise Value$10.14M

Total Cash (Recent Filing)$14.33M

Total Debt (Recent Filing)$1.29M

Price to Earnings (P/E)―

Beta1.71

Next Earnings

Aug 13, 2025

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding13,525,301

10 Day Avg. Volume185,917

30 Day Avg. Volume605,781

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.44

Enterprise Value/Revenue4.56

Enterprise Value/Gross Profit5.54

Enterprise Value/Ebitda-0.60

Forecast

1Y Price Target

$8.67

Price Target Upside459.35% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial SupportThe study is funded by a grant from the National Institute of Health, offsetting study expenses and providing financial support.

Regulatory DesignationsLaromestrocel has Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation, which could expedite its approval process.

Regulatory SupportThe FDA's ongoing commitment to streamlining approvals for rare diseases, particularly rare pediatric diseases, is expected to support the company's filing on a positive note.

Bears Say

Financial PerformanceLongeveron reported a net loss, and it is expected that the company will require additional capital.

Market PerformancePossible setbacks for Lomecel-B in other indications, notably Alzheimer's Disease, could impact market performance.

Trial RisksRisks include the potential failure of Lomecel-B in the ELPIS-II trial of HLHS patients and inability to obtain regulatory approval.

Longeveron News

Longeveron files to sell 3.85M shares of Class A common stock

16:05 EDT Longeveron (LGVN) files to sell 3.85M shares of Class A common stock Published first on TheFly...

3d ago

LGVN

Longeveron licenses patent for stem cell technology from University of Miami

Longeveron (LGVN) has licensed an issued US patent for a stem cell technology from the University of Miami....

18d ago

LGVN

Longeveron Gains FDA Approval for Laromestrocel Trial

An announcement from Longeveron ( ($LGVN) ) is now available. On July 8, 2025, Longeveron Inc. announced that...

29d ago

LGVN

Longeveron Receives Buy Rating: Promising Pipeline and Strategic Expansion into Pediatric Cardiomyopathy

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron, with a...

29d ago

LGVN

Longeveron announces FDA approval of IND application for laromestrocel study

Longeveron (LGVN) announced that the U.S. Food and Drug Administration has approved the Investigational New Drug application for...

1M ago

LGVN

Longeveron appoints Powell as Chief Business Officer

Longeveron (LGVN) announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In...

1M ago

LGVN

Positive Buy Rating for Longeveron Driven by Phase 2b Study Milestone and Favorable Market Conditions

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron (LGVN –...

1M ago

LGVN

Longeveron completes enrollment of Phase 2b trial of laromestrocel in HLHS

Longeveron (LGVN) has achieved full enrollment of the Phase 2b clinical trial evaluating its investigational cellular therapy laromestrocel...

1M ago

LGVN

Longeveron Elects New Director at Annual Meeting

Longeveron ( ($LGVN) ) just unveiled an announcement. On June 13, 2025, Longeveron held its annual stockholders’ meeting...

2M ago

LGVN

Longeveron management to meet with Roth MKM

Group Dinner Meeting to be held in Boston on June 16 hosted by Roth MKM. Published first on...

2M ago

LGVN

Buy Rating for Longeveron: ELPIS II Trial Progress and Financial Stability Highlighted

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Longeveron (LGVN – Research Report), retaining the...

3M ago

LGVN

Longeveron: Strategic Advancements and Promising Developments Drive Buy Rating

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Longeveron (LGVN – Research Report), retaining the...

3M ago

LGVN

Longeveron Reports Q1 2025 Progress and Financials

Longeveron Inc. ( ($LGVN) ) has released its Q1 earnings. Here is a breakdown of the information Longeveron...

3M ago

LGVN

Longeveron Re-approves Cash-to-Equity Program Strategy

Longeveron ( ($LGVN) ) has issued an announcement. On April 24, 2025, Longeveron Inc.’s Board of Directors confirmed...

3M ago

LGVN

LGVN FAQ

What was Longeveron Inc.’s price range in the past 12 months?

Longeveron Inc. lowest stock price was $1.14 and its highest was $2.89 in the past 12 months.

What is Longeveron Inc.’s market cap?

Longeveron Inc.’s market cap is $23.26M.

When is Longeveron Inc.’s upcoming earnings report date?

Longeveron Inc.’s upcoming earnings report date is Aug 13, 2025 which is in 5 days.

How were Longeveron Inc.’s earnings last quarter?

Longeveron Inc. released its earnings results on May 08, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.01.

Is Longeveron Inc. overvalued?

According to Wall Street analysts Longeveron Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Longeveron Inc. pay dividends?

Longeveron Inc. does not currently pay dividends.

What is Longeveron Inc.’s EPS estimate?

Longeveron Inc.’s EPS estimate is -0.35.

How many shares outstanding does Longeveron Inc. have?

Longeveron Inc. has 13,525,301 shares outstanding.

What happened to Longeveron Inc.’s price movement after its last earnings report?

Longeveron Inc. reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -10.067%.

Which hedge fund is a major shareholder of Longeveron Inc.?

Currently, no hedge funds are holding shares in LGVN

Company Description

Longeveron Inc.

Longeveron Inc. is a biotechnology company focused on developing cellular therapies for aging-related and life-threatening conditions. The company is engaged in the research and development of regenerative medicine, specializing in the use of medicinal signaling cells (MSCs) derived from donor bone marrow. Longeveron aims to harness the potential of these cells to address medical conditions associated with aging, such as frailty, and other severe diseases, thereby improving patient outcomes and enhancing quality of life.

Longeveron (LGVN) Earnings & Revenues

Historic Earnings Reports

LGVN Company Deck

LGVN Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a balanced view of Longeveron's progress, with strong revenue growth and regulatory advancements highlighted. However, challenges like enrollment delays in clinical trials and anticipated increases in future expenses were also noted. The call reflected cautious optimism about Lomecel-B's potential, supported by robust clinical data and regulatory designations, though future financial and strategic uncertainties remain.View all LGVN earnings summaries

LGVN Stock 12 Month Forecast

Average Price Target

$8.67

▲(459.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.9507692307692308,2.621538461538462,3.292307692307692,3.9630769230769234,4.633846153846154,5.304615384615385,5.975384615384615,6.6461538461538465,7.316923076923078,7.987692307692308,8.658461538461538,9.329230769230769,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.8484615384615384,2.416923076923077,2.985384615384615,3.5538461538461537,4.122307692307692,4.690769230769231,5.259230769230769,5.827692307692308,6.3961538461538465,6.964615384615385,7.533076923076924,8.10153846153846,{"y":8.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.643076923076923,2.006153846153846,2.3692307692307693,2.7323076923076925,3.0953846153846154,3.4584615384615383,3.821538461538462,4.184615384615385,4.547692307692308,4.9107692307692306,5.273846153846154,5.636923076923077,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.11,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >